Although it is not specifically approved for weight loss, it has shown positive results in clinical trials and real-world usage
Deciding whether to delay treatment depends on several factors, including the mothers health, how long breastfeeding is expected to continue, and the age and condition of the baby
#FDAApproval #IPF #PulmonaryFibrosis #Respiratory #DrugDevelopment #BoehringerIngelheim #Roche FDA Approves Boehringer Ingelheims JASCAYD (nerandomilast) for IPF The U.S
Prescriptions for GLP-1 receptor agonists like Ozempic and Mounjaro have surged in recent years, driven by their effectiveness in managing type 2 diabetes and supporting weight loss
They proposed an alternative to the Haller index, the optical index (the skin-to-skin transverse distance across the chest divided by the skin-to-skin posterior-anterior distance at the point of deepest deformity), as a method for measurement of chest wall deformities.[89] While they demonstrated the ability to quickly obtain reproducible results with scans and measurements performed by a variety of clinical and non-clinical staff, no direct comparisons were made to the Haller indices of patients in this study.[89] Daemen et al.[90] performed a systematic review that identified five studies comparing the use of 3D optical imaging to CT scans in the quantification of pectus severity
Anwendung Verwendung bei Diabetes mellitus Typ 2, kombiniert mit anderen Antidiabetika oder als Monotherapie, falls Metformin nicht vertragen wird oder kontraindiziert ist Parenterale Anwendung aufgrund der Peptidstruktur (Ausnahme: Semaglutid) Wirkmechanismus Analoga des physiologischen Inkretins GLP-1 Aktivierung des GLP-1-Rezeptors beeinflusst die glucoseabhngige Insulinfreisetzung und fhrt zur Senkung des Blutzuckerspiegels Zustzliche Effekte: Appetitminderung, verlangsamte Magenentleerung, Senkung der Glucagonfreisetzung Nebenwirkungen Gastrointestinale Beschwerden (z.B
